We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Foundation Medicine, IMS Health Collaborate
News

Foundation Medicine, IMS Health Collaborate

Foundation Medicine, IMS Health Collaborate
News

Foundation Medicine, IMS Health Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Foundation Medicine, IMS Health Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The combined offering will provide users with assessments of health outcomes and therapy effectiveness at the patient-anonymous level. IMS Health's RWE platform combines patient-anonymous claims, electronic medical record data, and biomarker data to provide health insights. Meantime, Foundation Medicine's FoundationCore is a database containing information from more than 43,000 clinical cases that have undergone testing by Foundation Medince's FoundationOne or FoundationOne Heme cancer profiling tests.

"As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs, treatment decisions, and outcomes for patient populations living with those cancers," Jon Resnick, IMS Health vice president and general manager of Real-World Evidence Solutions, said in a statement.

The collaboration will "drive a complete understanding of the oncology patient journey and improve clinical development and commercialization strategies," he added.

"There is recognition within the healthcare industry that rich and highly credible information will be the primary catalyst for the broad adoption of precision medicine, particularly in oncology," Michael Pellini, Foundation Medicine's CEO, said in the statement. 

Advertisement